Clinical Significance of CD147 in Children with Inflammatory Bowel Disease. (16th September 2020)

• Record Type: Journal Article
• Authors: Wang, Hongli; Ye, Jun; Liu, Ruitao; Chen, Guanhua; Zhao, Junhong; Huang, Ling; Yang, Fangying; Li, Musheng; Zhang, Shunxian; Jingxie, ; Xiong, Liya; Chen, Huan; Xu, Yuxin; Su, Mingmin; Xie, Yuanwen; Li, Songyu; Zheng, Fengfeng; Geng, Lanlan; Xu, Wanfu; Gong, Sitang
• Other Names: Fujiya Mikihiro Academic Editor.
• Is Part Of: BioMed research international. Volume 2020(2020)
• Publication Date: 2020-09-16
• Subjects: Medicine -- Periodicals; Biology -- Periodicals; Biotechnology -- Periodicals; Life sciences -- Periodicals; 610.5
• DOI: 10.1155/2020/7647181
• Languages: English
• ISSNs: 2314-6133

Abstract

Abstract : Background . CD147/basigin (Bsg), a transmembrane glycoprotein, activates matrix metalloproteinases and promotes inflammation. Objective . The aim of this study is to explore the clinical significance of CD147 in the pathogenesis of inflammatory bowel disease (IBD). Results . In addition to monocytes, the clinical analysis showed that there is no significance obtained in leucocyte, neutrophil, eosinophil, basophil, and erythrocyte between IBD and controls. Immunohistochemistry analysis showed that CD147 was increased in intestinal tissue of patients with active IBD compared to that in the control group. What is more, CD147 is involved in intestinal barrier function and intestinal inflammation, which was attributed to the fact that it has an influence on MCT4 expression, a regulator of intestinal barrier function and intestinal inflammation, in HT-29 and CaCO2 cells. Most importantly, serum level of CD147 content is higher in active IBD than that in inactive IBD or healthy control, which could be a biomarker of IBD. Conclusion . The data suggested that increased CD147 level could be a biomarker of IBD in children.